CNSP News and Press, CNS Pharmaceuticals Inc. From 06/08/22

CNS Pharmaceuticals (NASDAQ: CNSP) Scientific Advisory Board member Sigmund Hsu, MD, presented at the American Society of Clinical Oncology  (“ASCO”) annual meeting. Hsu’s presentation focused on the company’s ongoing clinical trial evaluating Berubicin for...

CNS Pharmaceuticals Announces Presentation of Ongoing Potentially Pivotal Berubicin Clinical Trial Design at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting PR Newswire HOUSTON , June 8, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc...

Wildfires usually occur in every year in similar areas, with those who live near these regions being exposed to carcinogenic pollutants on a long-term basis. Now new research has discovered a higher incidence of brain tumors and lung cancer in individuals who have been exposed to wildfires....

New research has found that genomic profiling may play a key role in the diagnosis and grading of brain tumors. More accurate and new diagnoses can be generated from genomic profiling. Here, alterations in the DNA that drive the growth of tumors are identified. Previously, diagnosis was de...

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its CEO John Climaco will be participating at the H.C. Wainwright Global Inv...

CNS Pharmaceuticals Announces Presentation at the H.C. Wainwright Global Investment Conference PR Newswire HOUSTON , May 24, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specia...

CNS Pharmaceuticals’ (NASDAQ: CNSP) novel anthracycline Berubicin, which has been developed to treat diseases with unmet need such as the deadly glioblastoma (“GBM”), appears to be the first anthracycline chemotherapy agent to successfully cross the blood-brain barrier...

Last week, Lantern Pharma Inc. announced that it would host a virtual webinar  on May 26, 2022, at 12 p.m.  ET. Lantern Pharma Inc. is an oncology-focused clinical stage biopharmaceutical firm that is leveraging its proprietary AI and machine learning platform to transform the ...

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced acceptance of its abstract for poster presentation at the American Society of Clin...

CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting PR Newswire HOUSTON , May 18, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS"...